Compare HLP & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLP | IVVD |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.2M | 212.6M |
| IPO Year | 2021 | 2021 |
| Metric | HLP | IVVD |
|---|---|---|
| Price | $3.42 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 406.8K | ★ 3.5M |
| Earning Date | 12-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $12.92 |
| Revenue Next Year | N/A | $44.18 |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.34 | $0.49 |
| 52 Week High | $4.90 | $3.01 |
| Indicator | HLP | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 35.94 |
| Support Level | $0.77 | N/A |
| Resistance Level | $4.69 | $0.66 |
| Average True Range (ATR) | 0.64 | 0.05 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 35.27 | 13.27 |
Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.